上海钻智生物科技

Shanghai Zuanzhi Biotechnology Co., Ltd. is a Chinese biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutics, including small molecules, biologics, and traditional Chinese medicine (TCM) formulations. The company operates in close integration with its affiliate, Changchun Intellicrown Pharmaceutical Co., Ltd., sharing leadership, intellectual property, and pipeline assets. Its clinical-stage pipeline includes Jinshengyuan Capsule, a 24-herb TCM formulation in Phase II development for liver cirrhosis ascites, and IMM-H014 (WS-117), an oral small-molecule Nrf1/Nrf2 pathway activator in Phase I/II trials for metabolic dysfunction-associated steatohepatitis (MASH/NASH). Additionally, the company is co-developing KN044, a recombinant humanized CTLA-4 single-domain antibody Fc fusion protein, in Phase I trials for advanced solid tumors in collaboration with Alphamab.